<div id="readability-page-1"><p>vTv Therapeutics (NASDAQ:VTVT - Get Free Report) will likely be posting its results before the market opens on Wednesday, May 13th. Analysts expect vTv Therapeutics to post earnings of $0.21 per share and revenue of $20.00 million for the quarter.</p><div><p><span></span><span>Get <strong>vTv Therapeutics</strong> alerts:</span></p></div><ul><li>Promising Upsides on these Biotech Penny Stocks</li></ul><p>vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last released its quarterly earnings data on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share for the quarter, beating analysts' consensus estimates of ($1.09) by $0.51.  On average, analysts expect vTv Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year. </p><h2>vTv Therapeutics Stock Performance</h2><p>NASDAQ:VTVT opened at $30.68 on Monday. The firm has a market cap of $120.88 million, a PE ratio of -9.16 and a beta of 0.26. vTv Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $44.00. The business has a 50 day moving average price of $36.42 and a 200-day moving average price of $33.66. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of equities research analysts recently commented on VTVT shares. BTIG Research  reiterated a &#34;buy&#34; rating and set a $49.00 price target on shares of vTv Therapeutics in a report on Wednesday, March 11th. Evercore began coverage on shares of vTv Therapeutics in a research report on Thursday, March 12th. They issued an &#34;outperform&#34; rating and a $44.00 price objective on the stock. Roth Mkm assumed coverage on shares of vTv Therapeutics in a research note on Thursday, January 22nd. They set a &#34;buy&#34; rating and a $58.00 price objective for the company. Wall Street Zen upgraded shares of vTv Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, March 14th. Finally, Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of vTv Therapeutics in a research note on Friday, March 27th. Five investment analysts have rated the stock with a Buy rating and one  has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $53.00.</p><p><b>View Our Latest Report on VTVT</b></p><h2>Hedge Funds Weigh In On vTv Therapeutics</h2><p>Hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. purchased a new stake in  vTv Therapeutics in the fourth quarter worth about $221,000.  Geode Capital Management LLC grew its holdings in shares of  vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock worth $1,128,000 after acquiring an additional 12,896 shares during the period.  Finally, 683 Capital Management LLC bought a new position in shares of  vTv Therapeutics in the 4th quarter worth approximately $731,000. Hedge funds and other institutional investors own  17.51% of the company's stock. </p><h2>vTv Therapeutics Company Profile</h2> (Get Free Report)<p>vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.  </p><p>The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.</p><h2>See Also</h2><ul><li>Five stocks we like better than vTv Therapeutics</li><li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li><li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li><li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li><li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlRWVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlRWVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in vTv Therapeutics Right Now?</h2><p>Before you consider vTv Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.</p><p>While vTv Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VTVT

<p>vTv Therapeutics (NASDAQ:VTVT) is set to release its earnings on Wednesday, May 13, with analysts expecting earnings of $0.21 per share and revenue of $20 million. The company previously reported a loss of $0.58 per share, exceeding estimates. Currently, vTv has a market cap of $120.88 million and a PE ratio of -9.16. Analysts have mixed ratings, with a consensus of "Moderate Buy" and an average target price of $53.00. Hedge funds hold 17.51% of the stock, indicating institutional interest in the company.</p>

vTv Therapeutics (VTVT) Projected to Post Earnings on Wednesday